Rachel M. Glicksman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rachel M. Glicksman has a total of 239 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Berlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
8 shared publications Padraig Warde
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada
6 shared publicationsPeter Chung
6 shared publications- Peter Chung
Radiation Medicine Program, Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON M5G 2M9, Canada
6 shared publications Alejandro Berlin
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Canada
5 shared publicationsAndrew Bayley
5 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 504
Initial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer
We report early toxicity outcomes after institutional implementation of prostate SBRT using 42.7 Gy in seven fractions delivered with either MR-guided adaptive SBRT (MRgSBRT) or CT-guided non-adaptive SBRT (CTgSBRT). Between July 2019 and May 2023, 216 patients received this regimen. Genitourinary (GU) and gastrointestinal (GI) toxicities were retrospectively assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Most patients had intermediate-risk disease (86%), and 14% had high-risk disease. Median prostate volume was 40 mL, and median baseline International Prostate Symptom Score (IPSS) was 8 among patients with available data. MRgSBRT and CTgSBRT were used in 100 (46%) and 116 (54%) patients, respectively. At a median follow-up of 19 months, 12- and 24-month grade ≥ 2 GU toxicity rates were 20.0% and 18.2%, while grade ≥ 2 GI toxicity rates were 3.5% and 3.6%, respectively. No statistically significant platform-related differences were detected; however, these comparisons were exploratory and potentially confounded by nonrandomized platform selection, treatment era, rectal-spacer use, adaptive workflow and differing PTV margins. On univariable analysis, baseline GU symptoms were associated with higher 12-month grade ≥ 2 GU toxicity (OR, 3.68; 95% CI, 1.52–10.37; p = 0.007), while prostate-volume category was not significantly associated with this endpoint.
- 25 August 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (9) , 504
Open AccessInitial Experience with MR-Guided or CT-Guided Stereotactic Body Radiotherapy for Prostate Cancer
We report early toxicity outcomes after institutional implementation of prostate SBRT using 42.7 Gy in seven fractions delivered with either MR-guided adaptive SBRT (MRgSBRT) or CT-guided non-adaptive SBRT (CTgSBRT). Between July 2019 and May 2023, 216 patients received this regimen. Genitourinary (GU) and gastrointestinal (GI) toxicities were retrospectively assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Most patients had intermediate-risk disease (86%), and 14% had high-risk disease. Median prostate volume was 40 mL, and median baseline International Prostate Symptom Score (IPSS) was 8 among patients with available data. MRgSBRT and CTgSBRT were used in 100 (46%) and 116 (54%) patients, respectively. At a median follow-up of 19 months, 12- and 24-month grade ≥ 2 GU toxicity rates were 20.0% and 18.2%, while grade ≥ 2 GI toxicity rates were 3.5% and 3.6%, respectively. No statistically significant platform-related differences were detected; however, these comparisons were exploratory and potentially confounded by nonrandomized platform selection, treatment era, rectal-spacer use, adaptive workflow and differing PTV margins. On univariable analysis, baseline GU symptoms were associated with higher 12-month grade ≥ 2 GU toxicity (OR, 3.68; 95% CI, 1.52–10.37; p = 0.007), while prostate-volume category was not significantly associated with this endpoint.
- Open Access
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Cancer in the Context of Global Health: A Gap in Understanding Among Global Health Leaders
PURPOSE: Cancer is a leading global health issue. It is unclear how global health leaders who are not directly or actively involved in cancer care perceive the importance of and opportunities within cancer control. We sought to examine their views on past, current, and future opportunities to optimize global cancer control. METHODS: We conducted a qualitative study using in-depth, one-on-one, semi-structured interviews with internationally recognized health thought leaders external to the field of cancer using purposive sampling. Interviews took place virtually from 2023 to 2024 and were recorded and transcribed, which were read and coded using thematic analysis with the aim of achieving thematic saturation. RESULTS: Twenty-seven individuals were contacted to participate: 18 (67%) responded to the invitation and 16 (59%) agreed to an interview. Six common overarching themes emerged from the interviews and were used to frame the analysis, including (1) Cancer is not well represented on the global health agenda; (2) Despite progress, cancer treatment is perceived to be costly and ineffective; (3) The concerns about treatment cost drive an emphasis on prevention; (4) The complexity of cancer control is a barrier; (5) Science and technology offer immense opportunity; and (6) Investment in cancer must rise to meet the need. CONCLUSION: Strong perceptions of cancer-related challenges and opportunities exist among health experts; understanding these opinions is crucial to advance cancer control and care.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Open AccessCancer in the Context of Global Health: A Gap in Understanding Among Global Health Leaders
PURPOSE: Cancer is a leading global health issue. It is unclear how global health leaders who are not directly or actively involved in cancer care perceive the importance of and opportunities within cancer control. We sought to examine their views on past, current, and future opportunities to optimize global cancer control. METHODS: We conducted a qualitative study using in-depth, one-on-one, semi-structured interviews with internationally recognized health thought leaders external to the field of cancer using purposive sampling. Interviews took place virtually from 2023 to 2024 and were recorded and transcribed, which were read and coded using thematic analysis with the aim of achieving thematic saturation. RESULTS: Twenty-seven individuals were contacted to participate: 18 (67%) responded to the invitation and 16 (59%) agreed to an interview. Six common overarching themes emerged from the interviews and were used to frame the analysis, including (1) Cancer is not well represented on the global health agenda; (2) Despite progress, cancer treatment is perceived to be costly and ineffective; (3) The concerns about treatment cost drive an emphasis on prevention; (4) The complexity of cancer control is a barrier; (5) Science and technology offer immense opportunity; and (6) Investment in cancer must rise to meet the need. CONCLUSION: Strong perceptions of cancer-related challenges and opportunities exist among health experts; understanding these opinions is crucial to advance cancer control and care.
- Open Access
- 3 July 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 398
Transition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes
MR-guided adaptive radiotherapy (ART) enables daily plan optimization for prostate cancer but is resource-intensive. This study evaluated dosimetric and clinical outcomes following transition from radiation oncologist (RO)-led to radiation therapist (RTT)-led MR-guided ART. All prostate cancer patients treated with MR-guided ART on a 1.5T MR-linac were retrospectively reviewed. Consecutive RO-led (September 2019–November 2021) and RTT-led (April 2022–October 2023) cohorts were compared, excluding the actual transition period. Toxicities (CTCAE v5.0), dose–volume metrics from daily adapted plans, target volume variation, and biochemical recurrence-free survival (BRFS) were analyzed. A total of 166 patients were included (78 RO-led, 88 RTT-led; median follow-up 40 and 35 months). Dosimetric differences between the cohorts were statistically small (n = 2 vs. n = 0), likely reflecting higher baseline urinary dysfunction; no post-treatment differences persisted. Early biochemical outcomes were comparable, with 36-month BRFS of 93.5% (RO-led) and 95.0% (RTT-led). RTT-led MR-guided ART achieved comparable dosimetric quality and early biochemical outcomes to RO-led workflows with adverse advents that resolved in the long term. With structured training and a mature practice setting, RTT-led ART represents a scalable model to support future adaptive radiotherapy practice.
- 3 July 2026
- Published by MDPI AG in Current Oncology
- Vol. 33 (7) , 398
Open AccessTransition from Oncologist- to Therapist-Led MRI-Guided Ultra-Hypofractionated Adaptive Prostate Radiation Therapy: Evaluation of Early Clinical Outcomes
MR-guided adaptive radiotherapy (ART) enables daily plan optimization for prostate cancer but is resource-intensive. This study evaluated dosimetric and clinical outcomes following transition from radiation oncologist (RO)-led to radiation therapist (RTT)-led MR-guided ART. All prostate cancer patients treated with MR-guided ART on a 1.5T MR-linac were retrospectively reviewed. Consecutive RO-led (September 2019–November 2021) and RTT-led (April 2022–October 2023) cohorts were compared, excluding the actual transition period. Toxicities (CTCAE v5.0), dose–volume metrics from daily adapted plans, target volume variation, and biochemical recurrence-free survival (BRFS) were analyzed. A total of 166 patients were included (78 RO-led, 88 RTT-led; median follow-up 40 and 35 months). Dosimetric differences between the cohorts were statistically small (n = 2 vs. n = 0), likely reflecting higher baseline urinary dysfunction; no post-treatment differences persisted. Early biochemical outcomes were comparable, with 36-month BRFS of 93.5% (RO-led) and 95.0% (RTT-led). RTT-led MR-guided ART achieved comparable dosimetric quality and early biochemical outcomes to RO-led workflows with adverse advents that resolved in the long term. With structured training and a mature practice setting, RTT-led ART represents a scalable model to support future adaptive radiotherapy practice.
- Open Access
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101164
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
- 6 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101164
Open AccessThe role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
- 1 March 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (3) , 326-336
Primary Retroperitoneal Lymph Node Dissection in Marker-Positive Clinical Stage II Nonseminomatous Germ Cell Tumors
Guidelines usually recommend chemotherapy rather than primary retroperitoneal lymph node dissection (pRPLND) for clinical stage II non-seminomatous germ cell tumours (NSGCTs) with elevated serum tumour markers (STMs). This study evaluated oncologic and perioperative outcomes of pRPLND in patients with marker-positive versus marker-negative CSII NSGCT. A retrospective review from our prospectively maintained database identified patients undergoing pRPLND (1983-2022). The primary endpoint was relapse-free survival (RFS). Secondary endpoints included cancer-specific survival (CSS), relapse location, and perioperative outcomes. Outcomes were compared using Kaplan-Meier analysis, log-rank testing, and multivariable COX regression. Among 207 patients with, 65 (31%) had elevated STMs (AFP: 12-376 µg/L; bHCG: 3-354 IU/L). Marker elevation was associated with higher relapse risk, with 5-year RFS of 75% vs. 93% for marker-negative patients (p<0.001). Five-year CSS was 96% vs. 100%, respectively (p=0.009). Of four cancer-specific deaths, two involved somatic transformation, one patient declined chemotherapy at relapse, and one death occurred during chemotherapy. Elevated AFP correlated with worse CSS, and dual marker elevation predicted greater relapse risk. Surgical complications rates did not differ between groups. Although elevated STMs are associated with increased relapse and mortality risk, pRPLND is associated with long-term disease control in approximately 75% of patients. Most relapses can be successfully treated in compliant individuals. Multidisciplinary decision-making should weigh relapse risk and potential salvage chemotherapy needs against the long-term morbidity of primary chemotherapy.
- 1 March 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 215 (3) , 326-336
Primary Retroperitoneal Lymph Node Dissection in Marker-Positive Clinical Stage II Nonseminomatous Germ Cell Tumors
Guidelines usually recommend chemotherapy rather than primary retroperitoneal lymph node dissection (pRPLND) for clinical stage II non-seminomatous germ cell tumours (NSGCTs) with elevated serum tumour markers (STMs). This study evaluated oncologic and perioperative outcomes of pRPLND in patients with marker-positive versus marker-negative CSII NSGCT. A retrospective review from our prospectively maintained database identified patients undergoing pRPLND (1983-2022). The primary endpoint was relapse-free survival (RFS). Secondary endpoints included cancer-specific survival (CSS), relapse location, and perioperative outcomes. Outcomes were compared using Kaplan-Meier analysis, log-rank testing, and multivariable COX regression. Among 207 patients with, 65 (31%) had elevated STMs (AFP: 12-376 µg/L; bHCG: 3-354 IU/L). Marker elevation was associated with higher relapse risk, with 5-year RFS of 75% vs. 93% for marker-negative patients (p<0.001). Five-year CSS was 96% vs. 100%, respectively (p=0.009). Of four cancer-specific deaths, two involved somatic transformation, one patient declined chemotherapy at relapse, and one death occurred during chemotherapy. Elevated AFP correlated with worse CSS, and dual marker elevation predicted greater relapse risk. Surgical complications rates did not differ between groups. Although elevated STMs are associated with increased relapse and mortality risk, pRPLND is associated with long-term disease control in approximately 75% of patients. Most relapses can be successfully treated in compliant individuals. Multidisciplinary decision-making should weigh relapse risk and potential salvage chemotherapy needs against the long-term morbidity of primary chemotherapy.
- Open Access
- 2 January 2026
- Published by Elsevier in Practical Radiation Oncology
- Vol. 16 (3) , e228-e233
Real-Time Magnetic Resonance Imaging Guidance to Enable Brachytherapy: A Case Series
- 2 January 2026
- Published by Elsevier in Practical Radiation Oncology
- Vol. 16 (3) , e228-e233
Open AccessReal-Time Magnetic Resonance Imaging Guidance to Enable Brachytherapy: A Case Series
- Open Access
- 23 November 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (1) , 154-163
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial
- 23 November 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 125 (1) , 154-163
Open AccessStereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial
- Open Access
- 15 November 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (2) , 101948
Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer
- 15 November 2025
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 11 (2) , 101948
Open AccessClinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer